Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (331-340 of 688) with videos related to

Pageof 69
Sort By:
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Circulation|February 23, 2005
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failureWilliam S Weintraub, Zefeng Zhang, Elizabeth M Mahoney, et al.
European Heart Journal|January 13, 2022
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisRajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2023
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registryPeter Moritz Becher, Gianluigi Savarese, Lina Benson, et al.
Circulation. Heart Failure|May 2, 2020
Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS TrialJoão Pedro Ferreira, Romain Eschalier, Kevin Duarte, et al.
European Journal of Heart Failure|March 22, 2017
Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fractionTor Biering-Sørensen, Sanjiv J Shah, Inder Anand, et al.
European Heart Journal|May 1, 2014
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder StudyGilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, et al.
Archives of Internal Medicine|January 26, 2005
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitusJames R Sowers, William B White, Bertram Pitt, et al.
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Pageof 69

Showing results (331-340 of 688) with videos related to

Sort By:
Pageof 69
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Circulation|February 23, 2005
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failureWilliam S Weintraub, Zefeng Zhang, Elizabeth M Mahoney, et al.
European Heart Journal|January 13, 2022
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisRajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2023
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registryPeter Moritz Becher, Gianluigi Savarese, Lina Benson, et al.
Circulation. Heart Failure|May 2, 2020
Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS TrialJoão Pedro Ferreira, Romain Eschalier, Kevin Duarte, et al.
European Journal of Heart Failure|March 22, 2017
Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fractionTor Biering-Sørensen, Sanjiv J Shah, Inder Anand, et al.
European Heart Journal|May 1, 2014
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder StudyGilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, et al.
Archives of Internal Medicine|January 26, 2005
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitusJames R Sowers, William B White, Bertram Pitt, et al.
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Pageof 69